CAS NO: | 51116-01-9 |
包装 | 价格(元) |
10 mM * 1 mL in Water | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | 8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is aPKG (protein kinase G)activator. 8-Bromo-cGMP sodium significantly inhibitsCa2+macroscopic currents and impairsinsulinrelease stimulated with high K+[1]. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses[2]. | ||||||||||||||||
体外研究 (In Vitro) | 8-Bromo-cGMP sodium (1-100 μM; 8 h) increases resistance of LLC-PK1 cells to CsA toxicity concentration-dependently[3]. Cell Viability Assay[3]
Western Blot Analysis[3]
| ||||||||||||||||
体内研究 (In Vivo) | 8-Bromo-cGMP sodium (0.3, 1, 3.0 nmol; intrathecal administration; 10 min before test) dose-dependently and significantly increases the tail-flick latency in Vincristine-treated mice to the level observed in vehicle-treated naive mice (male ICR mice, 4weeks of age and weighing 20 g). Vincristine (0.05 mg/kg 1 day after the pre-drug tail-flick latency, and then 0.125 mg/kg twice a week for 6 weeks) can induce painful neuropathy in mice[4]. | ||||||||||||||||
分子量 | 446.08 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C10H10BrN5NaO7P | ||||||||||||||||
CAS 号 | 51116-01-9 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 100 mg/mL(224.18 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |